Implementing mainstream germline genetic testing in breast cancer across Europe

Eduard Pérez-Ballestero, Sagal Ahmed Shire, Mateja Krajc, Arvīds Irmejs, Lenka Foretová, Sophie Frank, Tiina Kahre, Thomas van Overeem Hansen, Linetta Koppert, Anna Lena Burgemeister, Marc Tischkowitz, Judith Balmaña, Svetlana Bajalica-Lagercrantz*, ERN GENTURIS

*Corresponding author af dette arbejde

Abstract

The implementation of mainstream germline genetic testing in breast cancer patients has both benefits and challenges. Multiple aspects need to be considered for the outline of gene panels and the amount of pre-test genetic counselling. Mainstream genetic testing is mainly performed to stratify patients for targeted treatment. In addition, identification of germline pathogenic variants in cancer risk genes may have surgical implications, consequences for surveillance of other organs at risk of cancer, as well as family implications among relatives at risk. To ensure that patients are well informed, the introduction of mainstream genetic testing performed by non-genetic health care specialists requires an adapted pre-test counselling visit. Here, we review the literature and propose a web-based educational session and pocket guide to support implementation of mainstream testing in oncology practice.

OriginalsprogEngelsk
TidsskriftBJC Reports
Vol/bind4
Udgave nummer1
Sider (fra-til)3
ISSN2731-9377
DOI
StatusUdgivet - 3 feb. 2026

Fingeraftryk

Dyk ned i forskningsemnerne om 'Implementing mainstream germline genetic testing in breast cancer across Europe'. Sammen danner de et unikt fingeraftryk.

Citationsformater